Daily Stock List
Hubei Minkang Pharmaceutical Ltd. (HBMK)
FeedBlitz reported earlier on Hubei Minkang Pharmaceutical Ltd. (HBMK), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Trading on the OTCBB, Hubei Minkang Pharmaceutical Ltd. (Hubei Minkang), via their subsidiary Hubei Minkang Pharmaceutical Co., Ltd. (Hubei Minkang PRC), produces and markets Traditional Chinese Medicines (TCMs). Hubei Minkang PRC is a modern pharmaceutical company that produces and markets these medicines as well as some chemical pharmaceuticals in China. Founded in 1950, Hubei Minkang has their corporate headquarters in Yichang, Hubei, China.
Additionally, Hubei Minkang PRC markets their products to the United States, Japan, Canada, Singapore, Malaysia, Thailand and Hong Kong among other nations. The Company's products include pills, capsules, granules, oral solutions, tablets, syrups, mixtures, and injections. Hubei Minkang PRC has three Good Manufacturing Practice (GMP) certifications, with seven production lines capable of producing 10 different product types in more than 400 formulations and dosages.
The Company's strategy for producing high quality TCM products in an environmentally friendly manner using advanced technology and techniques, and distributing the products throughout China and globally is to concentrate production on their highest margin products; continuously improve production facilities and processes; lower production costs while maintaining product quality; and increasing direct sales while reducing distribution costs. Their strategy also includes acquiring control of raw material supply; developing and acquiring new products for manufacture; and expanding distribution throughout China and worldwide.
Earlier in 2012, Hubei Minkang Pharmaceutical announced that their Chinese subsidiary, Hubei Minkang PRC signed a Memorandum of Understanding (MOU) with Henan Wanlong Pharmaceutical Co., Ltd. (Henan Wanlong) of Zhengzhou, Henan, China with respect to a proposal for Hubei Minkang PRC to acquire 51 percent of Henan Wanlong to expand distribution and increase sales growth. Henan Wanlong is a sales distribution company focusing on supplying injection drugs to hospitals throughout China.
Hubei Minkang Pharmaceutical reported in November 2012 that during the next 12 months, management anticipates proceeding with expansion plans to acquire at least a 51 percent interest of Henan Wanlong for approximately $1.5 million and to increase commercialization of Hubei Minkang PRC's products. This includes the marketing distribution of existing and potential future products, which is anticipated to cost approximately $700,000.
Hubei Minkang PRC had sales of $3,339,825 and total cost of goods sold of $1,684,026 for the three-month period ended September 30, 2012. This is in comparison to sales of $3,181,496 and total cost of goods sold of $1,559,938 for the three-month period ended September 30, 2011. The net income (loss) was $243,203 and $(341,702) for three-month periods ended September 30, 2012 and 2011, respectively.
Hubei Minkang Pharmaceutical Ltd. (HBMK), closed Friday's trading session at $0.50, up 61.29%, on 7,065 volume with 5 trades. The average volume for the last 60 days is 834 and the stock's 52-week low/high is $0.15/$2.00.
ALR Technologies, Inc. (ALRT)
TaglichBrothers reported this month on ALR Technologies, Inc. (ALRT), AllPennyStocks, Street Beat, FeedBlitz, and OTC Showcase did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
ALR Technologies, Inc. is a leader in the emerging field of Chronic Disease Management utilizing in-home, patient-focused technology. Their products utilize internet-based technologies to facilitate health care providers the ability to monitor their patient's health and ensure adherence to health maintenance activities. The ALRT Health-e-Connect System is the principal product of the Company. ALR Technologies is headquartered in Richmond, Virginia.
The Company's Health-e-Connect is a web based patient management platform for medical professionals to improve compliance and adherence of care plans of patients in their homes. The programming of the System is to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases.
The ALRT Health-e-Connect System consists of application software and hardware devices, which allow health care providers to monitor the health status of patients in the time interval between patient visits to the doctor's office, and allow health care providers to monitor patient compliance to prescribed health management activities.
The System also allows primary health care providers to stay in touch with patients through SMS messages or through the Company's internal messaging system. Additionally, the System allows primary health care providers to communicate and collaborate with other health care providers involved and the patient's family by way of SMS messages or through the Company's internal messaging system. Furthermore, the System documents all patient interaction by the health care provider outside of clinic visits.
ALR Technologies also has their Reminder Devices. The ALRT Medication Reminder is compact in size; it can be used in a tabletop configuration or taken along with a user like a mobile phone or an organizer. At the programmed time of the day, the ALRT Medication Reminder provides both an audio and visual alarm to the patient reminding them of their medication schedule. Six ALRT Medication Reminder and two Pet Medication Reminder versions are available.
ALR Technologies, Inc. (ALRT), closed Friday's trading session at $0.043, up 7.50%, on 21,500 volume with 7 trades. The average volume for the last 60 days is 44,916 and the stock's 52-week low/high is $0.017/$0.1199.
Helmer Directional Drilling Corp. (EXLA)
StockMister reported today on Helmer Directional Drilling Corp. (EXLA), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
Founded in 2006, Helmer Directional Drilling Corp.'s intention is to review other business models and opportunities. The Company formerly went by the name Exclusive Apparel, Inc. They changed their corporate name to Helmer Directional Drilling Corp. in July of 2011. Helmer Directional Drilling has their headquarters in Chino, California. The Company's shares trade on the OTC Market's OTC Bulletin Board.
Concerning Helmer Directional Drilling's Results of Operations, the Company did not have any operating income from inception on September 8, 2006 through to September 30, 2012. For the nine months ended September 30, 2012, the Company recognized a net loss of $19,973. Expenses for the period consisted of costs primarily associated with legal, accounting and office expenses.
Concerning Liquidity and Capital Resources - as at September 30, 2012 - Helmer Directional Drilling had no capital resources. The Company will rely upon the issuance of common stock and additional capital contributions from shareholders to fund administrative expenses pending the full implementation of the Company's business model.
Ms. Georgette Mathers Wansor, is the Chief Executive Officer (CEO), President, Chief Financial Officer (CFO), Principal Accounting Officer, Secretary, and Director of Helmer Directional Drilling.
Earlier this month, Helmer Directional Drilling announced that the Company signed a Letter of Intent (LOI) to buy Excelsior Gold, Inc. (Excelsior) on December 13, 2012. Excelsior Gold is a Nevada company that has two mining properties located in the State of Washington and the State of Montana. Excelsior Gold's properties contain gold, molybdenum, tungsten, as well as silver.
According to Ms. Georgette Wansor, the Chief Executive Officer of Helmer Directional Drilling, "We are pleased to have this opportunity to acquire Excelsior and intend to close this acquisition no later than January 31, 2013."
Helmer Directional Drilling Corp. (EXLA), closed Friday's trading session at $0.0132, down 25.42%, on 2,132,349 volume with 62 trades. The average volume for the last 60 days is 29,909 and the stock's 52-week low/high is $0.022/$0.11.
Chisen Electric Corp. (CIEC)
SmallCap Fortunes, Whisper from Wall Street, OTCtipReporter, and SmallCapVoice reported earlier on Chisen Electric Corp. (CIEC), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Chisen Electric Corp. produces and sells sealed lead-acid motive batteries (Valve Regulated Lead-Acid motive batteries (VRLA batteries) in China's personal transportation device market. Their motive battery products sell under the Company's own brand name "Chisen". These products are primarily used in electric bicycles and are distributed and sold in China. Chisen Electric has their headquarters in Changxing, the People's Republic of China (PRC). The Company's shares trade on the OTC Bulletin Board.
Founded in 2003, Chisen Electric additionally focuses on providing wind and solar energy lead-acid storage batteries and lead-acid motive batteries for electric cars. The lead-acid motive battery is the preferred choice of electric bicycle manufacturers in the PRC. It accounts for 95 percent of the market share due to its cost efficiency.
Chisen Electric intends to invest resources to expand their sales and distribution networks through adding new distributors in key sales regions in China; developing new marketing strategies in different channels; improving communication between sales teams and distributors; and improving their brand awareness and promotion effort.
The Company's goal is to become the largest battery developer and producer with a first-class sales and service network in the PRC. Chisen has expansion plans in Changxing County (Zhejiang Province) and Jiangsu Province. They plan to explore the motive battery market for electric-powered motorcycles and electric cars. The Company will take advantage of their experience and expertise in producing lead-acid motive battery products for electric bicycles.
Chisen Electric plans to expand their product mix to include valve regulated lead-acid back-up batteries, the lithium-ion battery, lead-acid power storage batteries dedicated for solar and wind power and lead-acid motive batteries for electric cars. As pertains to the Company's corporate strategy, during the period ended September 30, 2012, they continued their strategy to implement a vertical integration strategy of producing lead plates at their Plant A. This has enabled the Company to reduce processing costs in comparison to the same period last year.
Chisen Electric Corp. (CIEC), closed Friday's trading session at $0.06, up 50.00%, on 20,000 volume with 3 trades. The average volume for the last 60 days is 4,050 and the stock's 52-week low/high is $0.025/$0.19.
DogInn, Inc. (DOGI)
Today we are highlighting DogInn, Inc. (DOGI), here at the QualityStocks Daily Newsletter.
DogInn, Inc. established to become a resource for travelers looking for information and resources pertaining to pet friendly accommodations, services, and products. The Company is focusing on incorporating improvements over the small number of existing Internet offerings in the pet friendly travel space. Incorporated in Nevada in July of 2010, DogInn is a development stage company and their development will occur in a number of phases. The Company lists on the OTC Bulletin Board.
Since their inception, DogInn has worked toward the introduction and development of their website that the Company will use to generate revenues. The Company's website (www.doginn.com) is a move away from traditional types of user interfaces to a simple interactive map-based presentation. The website's objective is maximum content and the Company will add new value-added features on a continual basis.
DogInn's website will be offered at no cost to the visitor. The website will integrate a fast and efficient search capability. It will be interactive, user-friendly, content rich, as well as graphically appealing.
The Company's Phase One plan is early stage development of the website that demonstrates the capabilities of the website, initial content development, and the development of a list of pet related service providers. The expectation is that Expenses related to Phase One will be less than $30,000. DogInn has completed their Beta site and they are further developing it. The Company expects to complete a launch-able site shortly. The Company currently has sufficient capital to complete this phase of their plan of operations.
Company Management believes that if they are successful in the completion of Phase One, the proof of concept will enable them to raise additional funds to fully develop the website and fund an expanded sales and marketing effort. In addition, the Company's Management anticipates hiring 1-2 permanent staff for this effort. They anticipate going live and rolling out the website.
DogInn expects this phase to cost approximately $100,000. The Company President will lead this phase of the plan of operations. If the Company is able to carry forward with this phase of their plan of operations, they expect the process to take approximately 6 months.
DogInn, Inc. (DOGI), closed Friday's trading session at $2.00, up 1,900.77%, on 2,500 volume with 1 trade. The average volume for the last 60 days is 167.
Independence Energy Corp. (IDNG)
Real Pennies, Penny Stock Rumble, OTCSHUB, and Investors Underground reported earlier on Independence Energy Corp. (IDNG), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Seal Beach, California, Independence Energy Corp. is an oil and gas exploration and development company focusing on projects in the U.S. The Company is looking to advance their existing projects further through development or offset drilling. They are also looking to expand their portfolio to include additional property interests in the U.S. Independence Energy lists on the OTC Market's OTCQB.
The Company's projects include the Quinlan Wells (Quinlan #1, Quinlan #2, Quinlan #3, and Quinlan #4 - three productive oil wells (Quinlan #1, #2, and #3) and one salt-water disposal well). The Quinlan Lease property is 120 acres. The Company currently holds a 10 percent interest in the three productive Quinlan Lease wells. Since Independence Energy acquired an interest in the project in late 2011, significant infrastructure and water handling upgrades were made at the site.
Furthermore, Independence Energy has a turnkey 5 percent Working Interest in the highly prospective MontCrest Energy Drilling Program #3 in Coleman County, Texas (the MontCrest Drill Program). The MontCrest Drill Program consists of a turnkey participation in two exploration wells targeting multiple oil bearing sand formations currently productive in the region. MontCrest Energy, Inc. is the project operator.
For the MontCrest Drill Program, the expectation is that the Shields-MEI #105-H Prospect Well will be drilled as a horizontal well targeting the Gardner Sandstone formation. In addition, the expectation is that the Vaughn-MEI #106 Prospect Well will be drilled to an estimated total depth of 4,650' to test a historically productive dolomite formation, as well as five other known formations at shallower depths.
Independence Energy announced in July 2012 that additional improvements were completed at their Quinlan Lease oil property in Oklahoma. The project operator reported that they successfully further upgraded a high capacity fluid pump used on-site. The upgraded pump has the capacity to transport up to 6,000 bbls of total fluids per day at pressures of up to 1,500 psi.
Independence Energy Corp. (IDNG), closed Friday's trading session at $0.0055, even for the day, on 795,034 volume with 37 trades. The average volume for the last 60 days is 84,527 and the stock's 52-week low/high is $0.005/$0.966.
Single Touch Systems, Inc. (SITO)
AllPennyStocks, Investor Update, and OTC Journal reported previously on Single Touch Systems, Inc. (SITO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Single Touch Systems, Inc. is a technology based mobile media solutions provider. The Company serves businesses, advertisers and brands. Their main products and services include Messaging and Notifications, a short message service (SMS) gateway, which provides a hosted messaging platform to SMS-enable any application, Website, or system; and Abbreviated Dial Codes. Single Touch Systems is based in Jersey City, New Jersey.
Currently, Single Touch sends out close to 900,000 mobile messages each day. Single Touch Systems provides one of the largest free-to-end-user voice and text mobile messaging programs for some of the largest retailers in the U.S. via a Master Services Agreement with AT&T. Retailers use the Company's scalable mobile messaging platform to engage with their customers in diverse ways including Reminder Messaging for pick up and deliveries, Mobile Coupons & Promotions, and New Product Launches, among others.
Through patented technologies and a modular, adaptable platform, Single Touch's multi-channel messaging gateway enables marketers to reach consumers on all types of connected devices. They reach these consumers with information that engages interest, drives transactions and strengthens relationships and loyalty.
Earlier this month, Single Touch Systems announced that Mr. Jon Sandelman joined Single Touch Systems' Board of Directors. Mr. Sandelman is a veteran Wall Street investor and fund manager. He is currently Managing Partner of Mercer Park, a private investment management firm in New York, New York. He was previously the Chief Executive Officer, Founder, and Chief Investment Officer of Sandelman Partners, a firm he founded in 2005.
Last week, Single Touch Systems announced that they sent one-half of a billion mobile messages (500,000,000) on behalf of their retail clients. This record number of messages was sent primarily over the past two years on behalf of national retailers, by way of voice and text, to U.S.-based mobile subscribers on an opt-in basis.
Single Touch Systems President and Chief Executive Officer, Mr. James Orsini, stated, "These core mobile messaging programs produce recurring revenues for Single Touch with visibility and predictability for the foreseeable future. We generate revenues for each message sent."
Single Touch Systems, Inc. (SITO), closed Friday's trading session at $0.61, up 10.91%, on 249,346 volume with 73 trades. The average volume for the last 60 days is 183,821 and the stock's 52-week low/high is $0.15/$0.55.
Aradigm Corp. (ARDM)
FeedBlitz, Stock Fortune Teller, HotStockChat, HotOTC, and CRWEFinance reported earlier on Greenbackers reported earlier on Aradigm Corp. (ARDM), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Based in Hayward, California, Aradigm Corp. is an emerging specialty pharmaceutical company that lists on the OTC Bulletin Board. The Company is developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease. Their product candidates address the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.
The design of their products is to improve patients' quality of life and overall treatment outcomes through enabling them to safely and painlessly self-administer aerosolized liquid medications directly to and through the lungs. All of these products utilize Aradigm's proprietary drug delivery technologies.
The performance of the AERx pulmonary drug delivery platform is because of its unique fine mist aerosol generation systems combined with patented breath control technology. For each therapeutic application, the AERx platform can be customized to deliver drugs and biologics to treat lung diseases topically or to transport therapeutics through the lung and into the bloodstream.
In November, scientists from the UK Defence Science and Technology Laboratory (Dstl) reported, in a preliminary study, that they demonstrated that a single dose of Aradigm's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague. In comparison, a single dose of oral ciprofloxacin administered 24 hours post-exposure provided no protection.
Ciprofloxacin is a widely prescribed antibiotic to treat infections of the lung frequently experienced by cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE) patients. It is often preferred due to its broad-spectrum anti-bacterial action. Aradigm has been granted orphan drug designation for liposomal ciprofloxacin for cystic fibrosis in the U.S. and the E.U., and for the combination of liposomal ciprofloxacin and free ciprofloxacin for BE in the U.S.
This month, Aradigm announced that they entered into a definitive agreement for the sale of common stock to two existing shareholders, in a private placement for aggregate gross proceeds of $6 million. The proceeds will further development of inhaled ciprofloxacin for the treatment of severe respiratory diseases.
Aradigm Corp. (ARDM), closed Friday's trading session at $0.13, up 1.56%, on 107,680 volume with 17 trades. The average volume for the last 60 days is 42,150 and the stock's 52-week low/high is $0.085/$0.18.
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.065, even with yesterday's close. The stock’s average daily volume over the past 60 days is 58,069, and its 52-week low/high is $0.0069/$0.07.
Viscount Systems, Inc. announced publication of a report on the company today by leading independent research firm on emerging technology companies, SoundView Technology Group. In the report entitled, “Viscount Systems: The IT Bridge for Physical Security,” SoundView details the advantages of the company's unified software platforms for implementing robust building security and ingress/egress solutions, as well as emergency planning.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
SoundView Technology Group Issues Research Report on Viscount Systems
Viscount Systems Appoints Dennis Raefield as Chief Operating Officer
Viscount Announces Completion of $500,000 Private Placement
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.03, up 7.14%, on 1,652,076 volume with 49 trades. The stock’s average daily volume over the past 60 days is 1,949,121, and its 52-week low/high is $0.0275/$0.179.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Receives Preliminary Approval for Sale of Losses from State of NJ Economic Development Authority
Advaxis Presents at NYC MedTech Program
Advaxis Updates Phase 2 Cervical Cancer Trial Data
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $8.01, off by 1.11%, on 10,950 volume with 23 trades. The stock’s average daily volume over the past 60 days is 35,994, and its 52-week low/high is $0.72/$10.01.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
Umbrella Research Initiates Coverage on TNI BioTech
TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
TNI BioTech Inc., and Hubei Qianjiang Pharmaceuticals Co., Ltd., Announce Venture Partnership for the Development of New Drug for Cancer Therapies
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.19, off by 2.16%, on 143,227 volume with 109 trades. The stock’s average daily volume over the past 60 days is 200,678, and its 52-week low/high is $0.17/$0.42.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium Announces Patent Award For Rights To Gene Therapy for Coronary Heart Disease, Resolves Long-standing IP Competition
Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments
Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
Earlier this morning, Viscount Systems, a developer and manufacturer of IT-based solutions for physical security systems, announced that SoundView Technology Group has published a detailed report on the company. Those who wish to receive a copy of the report should email Scott Greiper at firstname.lastname@example.org.
SoundView Technology Group is known for their independent research on emerging technology companies. The research firm combines major thematic forces where technology is involved and analysis to identify the most promising companies and investment opportunities. SoundView distributes its research to institutions, investors, company managers, and individuals via proprietary platforms, the internet, and social networks.
Viscount Systems designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company’s products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
For more information on Viscount Systems and its cutting-edge technologies, visit www.Viscount.com
Mantra Venture Group looks back on a tremendously successful and productive 2012 while heralding in a number of innovative prospects for 2013.
“We’ve had an exciting and beneficial year,” said Company president and CEO, Larry Kristof. “We’ve developed strategic partnerships in addition to securing important patents. I’m confident we will continue to expand upon the successful foundations built in 2012.”
Highlights of 2012 include:
- Substantial capital injection in the First Quarter that ensured the implementation of the Company’s Electrochemical Reduction of Carbon Dioxide (ERC) technology;
- Expansion of the management team in the Second Quarter with the addition of Tom Unger as Vice President of Corporate Finance. Mr. Unger is a successful entrepreneur and venture capitalist;
- Securing the patent for the Electrochemical Reduction of Carbon Dioxide technology;
- Technology Development Agreement with Powertech, a proven leader in designing and testing clean technology solutions. Powertech will provide testing at its facility of the ERC technology and offer its expertise to advance the technology behind the process. Powertech has developed a CO2 concentration technology which will increase the CO2 content of the Lafarge stack gases from 20% to 80%, making it much easier for the CO2 conversion process. Powertech will begin the scaleup of the concentrator in January to match the requirements for the Lafarge pilot unit;
- A Technology Development Agreement with Tekion (Canada) Inc to accelerate the field trials for the ERC process. Tekion has developed some very novel electrode designs and is currently working on materials screening prior to scale up. These new designs will provide some significant patent opportunities and provide additional flexibility in the design of the Lafarge trial unit;
- Securing a patent for the mixed reactant fuel cell (MRFC) technology;
- Completing the construction of a fully integrated ERC and MRFC demonstration unit.
“We are continuing to further develop our ERC and MRFC technology,” said Company president and CEO, Larry Kristof. “2013 will see the Company forging more strategic partnerships as we continue to develop and refine the technology.”
Highlights for 2013 include:
- Identifying an engineering partner and additional strategic partners;
- Construct and install the ERC demonstration plant at the Lafarge cement plant in Richmond, BC ;
- Further expansion of the management team;
- Receiving additional ERC and MRFC technology patents;
- Applying for new technology patents;
- Continuing to highlight the ERC and MRFC technology to investors and industry leaders at international trade shows.
Mantra Venture Group wishes you and yours a happy, healthy and prosperous New Year. As you appreciate the final days of 2012 and prepare to ring in the New Year, enjoy our latest video demonstrating the innovative ERC and MRFC technology that converts CO2 into renewable energy: http://www.youtube.com/watch?v=o5ORK48MquI.
New Western Energy continues piecing together an extremely solid portfolio of working interests across the rich hydrocarbon targets of the Gulf States region, with noted small-cap research firm, Zacks Equity Research, even bumping the price target ten cents recently (Dec 21) to $1.40 on the company’s strong market cap to reserves ratio among others things, especially in light of the new Fields Lease acquisition in Kansas (Dec 20).
The 300-acre Fields Lease (100% WI) has expanded an already firm, contiguous foundation in the Chautauqua Arch area held by the company via their 1.7k-acre B&W Ranch (90% WI, acquired in March of 2012) and 550-acre Smith Leases (90% WI, acquired in May of 2012). This brings NWTR up to 2,550 acres in prime Pennsylvanian age Cherokee basin shale, all of it contiguous (with southern district targets in the pre-Pennsylvanian reservoirs like the Weiser Sands and Wayside Sands). The gas and oil here flows from primarily the Mulky Shale and Weiser Sands reservoirs, offering up a target rich environment for new wells, and the company is laser-focused on acquiring additional interests in the Chautauqua County area (and elsewhere) through carefully selected acquisitions/partnerships.
Looking at the new reserve estimate, post the Fields Lease acquisition, Zacks was confident of the upwardly revised price target from eleven days prior, showing some really nice forward revenue projections as well (ramping from $0.20M in Q1 2013 to $1.7M in Q4 the following year). The B&W Ranch Lease (engineering, reserve, and geological analysis via the Apr 25 agreement with Carroll Energy, LLC) for instance has such a great target array there is already obvious potential for three to four oil formation discoveries by NWTR, in addition to an equal number of gas formation discoveries. Both production zones are in quite shallow territory and in general we have reservoirs at a very manageable depth of around 600 to 1.4k feet across the leases, offering shareholders an approachable, economically feasible growth outlook.
Turning further south past where the Central Oklahoma platform meets the Cherokee basin, across the border and east of Tulsa in Rogers County, are the company’s Oklahoma assets. These assets include the over 120-acre Glass Lease (60.94% NRI) consisting of 14 wells secured via joint-venture with RC Oil Company back in 2009 and the 150-acre Glass Lease (60.94% NRI), also via the RC Oil JV. The properties are now overseen/operated by Petroleum Energy Management Co. (PEMCO), who secured the interests towards the end of 2011.
PEMCO wrapped Phase I of the newest work-over program on the Glass Lease in September of 2012, with emphasis being primarily on jacking up output from the 6 production wells through redirected pressure maintenance and plugging of extraneous wells. Production continues on the site and the indicated probable/recoverable reserves were last calculated at around 287k bbls of oil from the Bartlesville Formation. The Phillips Lease has seven wells and one saltwater injection well, with shallow targets in the 500-foot range and 20 year old wells that are still producing like champs. The outlook is quite positive, especially considering the abundance of production in the district itself and ample room to work with at 150 acres.
Jumping further to the south we have a set of five leases in Texas, located in Jones and Shackelford Counties, which make up the bulk of the company’s remaining oil and gas production interests. It’s a good idea to look at the Moran Lease (12 wells, eight lease units total) in Shackelford County first, as this 680-acre property recently (Oct 16) saw commencement of a comprehensive work-over program via the company’s wholly-owned, Royal Texan Energy Co. subsidiary, focused on the Sam Cannon Well Unit. The two wells (#1 and #4) which make up the Sam Cannon churned out some 146.6k bbls of oil and 4.851M MCF of gas from August 1966 to February 1997, seeing 196 BOPD figures ($1.5M per quarter at current prices). Production is in the Mississippian zone (with a deeper Ellenberger secondary) at 3.9k feet but a packer and tubing section is lodged at around 2.5k feet in the #1 and was being pulled at last report from the well bore in advance of production restart.
For more information on New Western Energy, visit www.NewWesternEnergy.com
PositiveID, a developer of airborne bio-threat detection systems for the U.S. homeland defense industry and creator of advanced technologies for rapid medical testing and diabetes management, last week entered into a license and teaming agreement with The Boeing Company.
Per the agreement, which includes a license fee to PositiveID of $2.5 million, Boeing has the exclusive license to manufacture and sell PositiveID’s M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security’s (DHS) BioWatch Generation 3 opportunity, as well as other opportunities that may arise in the North American market.
PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market, as well as keep the right to sell M-BAND units, reagents, and assays in international markets.
PositiveID’s M-BAND is a bioaerosol monitor with full capability to collect, process, detect, and analyze air samples for the detection of bacteria, viruses, and toxins. Results from individual M-BAND instruments are reported through a secure wireless network in real time to give an accurate and up to date status. The M-BAND touts significant hardiness, operating from -25 to 125 degrees Fahrenheit, for both indoor and outdoor settings. Toxin analysis takes approximately 40 minutes.
For more information, visit www.PositiveIDCorp.com
Today's Top 3
The Online Investor
The QualityStocks Public Company Sponsor News